Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)